Masterclass: Investing In Oncology - Digital Pathology and Real World Evidence and Data

Digital pathology has shown many advantages such as improved sample analysis, fewer errors, reduced long-term costs, and better diagnostic results in less time, which ultimately leads to better patient outcomes. Many investors and pharma companies have realized the potential of digital pathology technologies in oncology, as well as the use of real-world evidence (RWE) and data (RWD). Join this masterclass led by Bill Taranto, President of the Merck Global Health Innovation Fund, to discuss and learn more about: